Abstract
Incentives to stimulate greater industry pharmaceutical innovation are in place in most OECD countries. However, they are never more needed than for so-called “neglected diseases” (NDs). These are diseases such as malaria, tuberculosis and helminth infections that afflict hundreds of millions of poor patients in developing countries. We focus here on how to stimulate industry innovation for these diseases, and on the circums tances in which alternative routes of innovation will be needed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
The Global Fund to Fight AIDS, TB and Malaria (GFATM): Introduction to the Affordable Medicines Facility — malaria. Available at: http://www.theglobalfund.org/content/pressreleases/pr_090417_Factsheet. pdf (accessed 8 November 2010).
Hollis A, Pogge T, et al. The Health Impact Fund: Pay-for-Performance (WHO Expert Working Group Submission 2009). Available at: http://www.who.int/phi/HIF.pdf (accessed 8 November 2010).
Light D. Advanced Market Commitments: Current Realities and Alternate Approaches: HAI Paper Series. 2009. Available at: http://www.haiweb.org/31032009/27%20Mar%202009%20AMC%20Current% 20Realities%20&%20Alternate%20Approaches%20FINAL.pdf (Accessed 8 November 2010).
IHP — Taskforce on Innovative Financing for Health Systems: Raising and Channeling Funds. Working Group 2 report (2009). Available at: http://www.internationalhealthpartnership.net/CMS_files/userfiles/ 090817%20WORKING_GROUP_2(1).pdf (accessed 8 November 2010).
IAVI (2009). Financing the Accelerated Development of Vaccines for AIDS, TB, and Malaria: Design of the PDP Financing Facility and an Analysis of Its Feasibility (a Report to Aeras, IAVI, and MVI). Available at: http://healthresearchpolicy.org/sites/healthresearchpolicy.org/files/PDPFF%20financing% 20vaccines%20for%20AIDS,%20TB,%20and%20malaria.pdf (accessed 8 November 2010).
Grabowski H, Ridley D, Moe J. Priority Review Vouchers to encourage innovation for neglected diseases. 2008. Available at: http://www.law.harvard.edu/programs/petrie-flom/workshops_confe-rences/2008_workshops/Grabowski.pdf (accessed 8 November 2010).
Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Affairs. 2006, 25:313–324.
Novartis media release. September 15, 2008. Available at: http://www.novartis.com/newsroom/mediareleases/ en/2008/1251164.shtml. Accessed 2 November 2010
Di Masi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics. 2003;22:151–185.
UNITAID. Proposals for New and Innovative Sources of Funding Medicines Patent Pool. 2009. Availa ble at: http://www.who.int/phi/UNITAID.pdf (accessed 8 November 2010).
IFPMA Submission to the Public Hearing on Proposals for R&D Financing. Available at: http://www.who.int/phi/IFPMA.pdf (accessed 8 November 2010).
Everts S. Open-Source Science — Online research communities aim to unite scientists worldwide to find cures for neglected diseases. Chemical and Engineering News. 2006; 84(30):34–35. Available at: http://pubs.acs.org/cen/index.html (accessed 8 November 2010).
Pelfrene E. Article 58: A route to scientific opinion. EMEA; 2008. Available at: http://www.kaisernetwork. org/health_cast/uploaded_files/Article_58_A_Route_to_Scientific_Adoption_Eric_ Pelfrene_5.6.08%5B1%5D.pdf (accessed 8 November 2010).
Moran M, Guzman J, Ropars AL, Illmer A. The role of Product Development Partnerships in research and development for neglected diseases. International Health. 2010;2(2). Available at: http://www.internationalhealthjournal.com/article/S1876-3413(10)00026-4/abstract (accessed 8 November 2010).
Health Action International (HAI). Response to the Expert Working Group on Alternative Finan — cing. 2009. Available at: http://www.who.int/phi/HAI.pdf (accessed 8 November 2010).
Celgene media release, January 27, 2005. Available at: http://ir.celgene.com/phoenix.zhtml?c= 111960&p=irol-newsArticle_Print&ID=667281&highlight=.(Accessed 2 November 2010).
Rights and permissions
Copyright information
© 2011 Springer Healthcare Ibérica SL.
About this chapter
Cite this chapter
Moran, M. (2011). Incentives for innovation: Neglected diseases. In: Incentives for Research, Development, and Innovation in Pharmaceuticals. Economía de la Salud y Gestión Sanitaria. Springer Healthcare, Madrid. https://doi.org/10.1007/978-84-938062-7-9_3
Download citation
DOI: https://doi.org/10.1007/978-84-938062-7-9_3
Publisher Name: Springer Healthcare, Madrid
Print ISBN: 978-84-938062-1-7
Online ISBN: 978-84-938062-7-9
eBook Packages: MedicineMedicine (R0)